CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Login
View profile
Log out
Welcome back

Click below to sign in and see leads, RFIs or statistics

Sign in

Sign out
- Search Impressions
  
  3 287
- Page views
  
  324
- Request for information
  
  54
Subscribe

Innovative combination Finasteride + Tadalafil

Innovative combination Finasteride + Tadalafil

Product Description

Innovative combination Finasteride + Tadalafil

Both products individually are approved for BPH (Benign prostatic hyperplasia) in Europe.
The most frequent adverse reactions are impotence and decreased libido in Finasteride. The benefit of Tadalafil is early onset of therapeutic effect and reduction of finasteride-induced adverse events (e.g. erectile dysfunction)
Co-administration of Tadalafil 5 mg and finasteride 5 mg is recommended by European association of Urology (EAU – Guideline for Management of Non-neurogenic Male LUTS) and approved by FDA for BPH for up to 26 weeks
For more details contact Vaibhav Sharma, Head of Value added products ([email protected] )

Zentiva

Zentiva

CZ
2019

On CPHI since

Compare Add to favorites Added to favorites

Categories

Finished Dosage Forms (Products) Tablets

Sales Markets

Africa
East Asia (e.g. China, Japan, Korea)
Europe - EU countries
Europe - non EU (e.g. UK, Russia, ex-CIS countries)
South Asia (e.g. India, Pakistan, Sri Lanka)
South East Asia (e.g. Thailand, Philippines, Singapore)

Zentiva

Zentiva

CZ
2019

On CPHI since

Compare Add to favorites Added to favorites

More Products from Zentiva (4)

Product Zent2U - Zentiva B2B Platform

Zent2U (www.zent2u.com) is a B2B platform of Zentiva established in 2019 to collaborate with customers on:

- Licensing-out dossiers developed by Zentiva

- Co-development opportunities by co-financing Zentiva's products in development

- CMO services by Zentiva in production ...

Compare
Product Value Added Dasatinib

Value added Dasatinib (Teaser attached) • Dasatinib is a targeted therapy used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) • Current available products on the market are not completely absorbed by those patients ...

Compare
Product Value Added Abiraterone

Value added Abiraterone • Abiraterone is a medication used to treat prostate cancer • The recommended dose is 1,000 mg as a single daily dose that must not be taken with food. • Administering with food results up to a 10-fold (AUC) and up to a 17-fo...

Compare
Product CDMO

Services.

Compare

Zentiva resources (1)

Brochure Corporate Presentation